Laura Geraldino Pardilla, MD
Rheumatology · New York, NYNPI 1891952768
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Aurinia Pharma U.S., Inc. accounts for 63.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $63,123, 2.4 times the $26,715 reported in 2019. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $503.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$143K
- E.r. Squibb & Sons, L.L.C.$53K
- Janssen Scientific Affairs, LLC$7K
- Novartis$6K
- Pfizer$6K
- AstraZeneca$3K
- plus $6K from 12 others
Across 94 payments — averaging $16,081 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$333K
- Astrazeneca UK Limited$326K
- Boehringer Ingelheim$223K
- AstraZeneca$220K
- Genentech, Inc.$155K
- GSK$96K
- plus $159K from 6 others
What the payments were for
- Consulting fees$47,11121%
- Speaking & faculty fees$117,41352%
- Travel & lodging$51,45723%
- Food & beverage$8,3674%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 188 | $143,404 |
| E.r. Squibb & Sons, L.L.C. | 34 | $52,758 |
| Janssen Scientific Affairs, LLC | 82 | $6,951 |
| Novartis | 64 | $6,171 |
| Pfizer | 21 | $5,831 |
| AstraZeneca | 5 | $3,417 |
| Biogen | 10 | $1,313 |
| Vertex | 2 | $1,125 |
| AbbVie | 10 | $1,113 |
| Halozyme Inc | 1 | $590 |
| Genentech, Inc. | 16 | $476 |
| Madrigal Pharmaceuticals | 2 | $260 |
| Bristol Myers Squibb | 5 | $240 |
| GSK | 2 | $167 |
| Sanofi | 1 | $150 |
| Intercept Pharmaceuticals, Inc. | 1 | $146 |
| Johnson & Johnson | 1 | $137 |
| Amgen | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$224,367 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 83 | $546,113 |
| Orencia ClickjectAbatacept | 42 | $232,182 |
| Enbrel SureclickEtanercept | 32 | $223,358 |
| OrenciaAbatacept | 21 | $111,943 |
| Actemra ActpenTocilizumab | 23 | $108,444 |
| ActemraTocilizumab | 22 | $103,800 |
| Humira(Cf) PenAdalimumab | 13 | $96,963 |
| BenlystaBelimumab | 12 | $54,389 |
| RasuvoMethotrexate/Pf | 28 | $15,169 |
| Mycophenolate Mofetil | 60 | $12,956 |
| Hydroxychloroquine Sulfate | 201 | $7,576 |
| Diclofenac Sodium | 92 | $7,532 |
| Leflunomide | 71 | $6,211 |
| MethotrexateMethotrexate Sodium | 191 | $4,465 |
| Colchicine | 33 | $1,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,113 | $546,11383 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $52,758 | $111,94321 claims |
| Genentech, Inc.Actemra | $476 | $103,80022 claims |
| GSKBenlysta | $167 | $54,38912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.